Home> Products> Inhibitors> LX-4211-CAS 1018899-04-1
price inquiry for CAS:1018899-04-1, Product:LX-4211

LX-4211 CAS: 1018899-04-1

Category: Inhibitors
Product Name: LX-4211
Cat No: I000136
CAS No: 1018899-04-1
Synonyms: (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylsulfanyloxane-3,4,5-trio
Molecular Formula: C21H25ClO5S
Molecular Weight: 424.9
SMILES: ClC(C=CC([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](SC)O1)=C2)=C2CC3=CC=C(OCC)C=C3
InChI: InChI=1S/C21H25ClO5S/c1-3-26-15-7-4-12(5-8-15)10-14-11-13(6-9-16(14)22)20-18(24)17(23)19(25)21(27-20)28-2/h4-9,11,17-21,23-25H,3,10H2,1-2H3/t17-,18-,19+,20+,21-/m1/s1
InChIKey: QKDRXGFQVGOQKS-CRSSMBPESA-N
Solubility: 10 mM in DMSO
Target: SGLT
Storage: Store at -20°C
CAS 1018899-04-1,LX-4211
  • Description

LX-4211 is a potent dual SGLT2/1 inhibitor; Antidiabetic agents.
IC50 value:
Target: SGLT1/2
LX4211 enhanced urinary glucose excretion by inhibiting SGLT2-mediated renal glucose reabsorption; markedly and significantly improved multiple measures of glycemic control, including fasting plasma glucose, oral glucose tolerance, and HbA(1c); and significantly lowered serum triglycerides. LX4211 also mediated trends for lower weight, lower blood pressure, and higher glucagon-like peptide-1 levels. In a follow-up single-dose study in 12 patients with T2DM, LX4211 (300 mg) significantly increased glucagon-like peptide-1 and peptide YY levels relative to pretreatment values, probably by delaying SGLT1-mediated intestinal glucose absorption [1]. LX4211-treated mice and SGLT1-/- mice also had increased GLP-1 AUC values, decreased glucose-dependent insulinotropic polypeptide (GIP) AUC values, and decreased blood glucose excursions during the 6 hours after a challenge with oral glucose alone [2].

  • Spec

Appearance:Solid powder
Purity: > 98%

  • References


[1]. Zambrowicz B, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69.
[2]. Powell DR, et al. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther. 2013 May;345(2):250-9.


price inquiry for CAS:1018899-04-1, Product:LX-4211